Skip to main content
SpringerLink
Log in

Burkitt lymphoma

  • Chapter
  • First Online:
Management of Lymphomas: A Case-Based Approach

  • 736 Accesses

Abstract

The patient is a 61-year-old female with a past history of hypertension who presented with a few days’ history of severe abdominal pain and nausea/vomiting. Abdominal X-ray showed partial small bowel obstruction.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Magrath I. Epidemiology: clues to the pathogenesis of Burkitt lymphoma. Br J Haematol. Mar 2012;156:744–756.

    Google Scholar 

  2. Slack GW, Gascoyne RD. MYC and aggressive B-cell lymphomas. Adv Anat Pathol. 2011;18:219–228.

    Google Scholar 

  3. Blum KA, Lozanski G, Byrd JC. Adult Burkitt’s leukemia and lymphoma. Blood. 2004;104:3009–3020.

    Google Scholar 

  4. Magrath I, Adde M, Shad A, et al. Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol. 1996;14:925–934.

    Google Scholar 

  5. Mead G, Barrans SL, Qian W et al. A prespective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial). Blood. 2008;112;2248–2260.

    Google Scholar 

  6. Barnes JA, LaCasce AS, Feng Y, et al Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt’s lymphoma: a retrospective analysis. Ann Oncol. 2011;22:1859–1864.

    Google Scholar 

  7. Thomas DA, Faderl S, O’Brien S, et al. Chemoimmunotherapy with hyper-CVAD plus Rituximab for the treatment of adult Burkitt and Burkitt type lymphoma or acutelymphoblastic leukemia. Cancer. 2006;106:1569–1580.

    Google Scholar 

  8. Dunleavy K, Pittaluga S, Shovlin M et al. Low-intensity therapy in adults with Burkitt’s lymphoma. N Engl J Med. 2013;369:1915–1925.

    Google Scholar 

  9. Hoelzer D, Walewski J, Dohner H, et al. Improved outcome of adult Burkitt lymphoma/leukemia patients with rituximab and intensive chemotherapy: report of a large prospective multicenter trial. Blood. 2014;124:3870–3879.

    Google Scholar 

  10. Rizzieri DA, Johnson JL, Byrd JC, et al. Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10 002. Br J Haematol. 2014;165:102–111.

    Google Scholar 

  11. Sweetenham JW, Pearce R, Taghipour G, Blaise D, Gisselbrecht C, Goldstone AH. Adult Burkitt’s and burkitt-like non-Hodgkin’s lymphoma-outcome for patients treated with high-dose therapy and autologous stem-cell transplantation in first remission or at relapse: results from The European Group for Blood and marrow Transplantation. J Clin Oncol. 1996;14:2465–2472.

    Google Scholar 

  12. Noy A, Kaplan L, Lee J. A modified dose intensive R-CODOX-M/IVAC for HIV-associated Burkitt and atypical Burkitt lymphoma (BL) demonstrates high cure rates and low toxicity: prospective multicenter phase II trial of the AIDS Malignancy Consortium. Blood. 2012;122:639.

    Google Scholar 

  13. Ribera JM, García O, Grande C, et al. Dose-intensive chemotherapy including rituximab in Burkitt's leukemia or lymphoma regardless of human immunodeficiency virus infection status: final results of phase 2 study. Cancer. 2012;119:1660–1668.

    Google Scholar 

  14. Magrath I, Adde M, Shad A, et al. Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol.1996;14:925.

    Google Scholar 

  15. Mead GM, Sydes MR, Walewski J, et al. An International evaluation of CODOX-M and CODOX-m alternating with IVAC in adult Burkitt’s lymphoma: results of Unites Kingdom Lymphoma Group LY06 Study. Ann Oncol. 2002;13:1264.

    Google Scholar 

  16. Mead GM, Barrans SL, Qian W, et al. A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 Trial). Blood. 2008;112:2248.

    Google Scholar 

  17. Lacasce A, Howard O, Lib S, et al. Modified magrath regimens for adults with Burkitt and Burkitt-like lymphomas: preserved efficacy with decreased toxicity. Leuk Lymphoma. 2004;45:761.

    Google Scholar 

  18. Thomas DA, Faderl, O’Brien S, et al. Chemoimmunotherapy with Hyper-CVAD plus rituximab for the treatment of adult Burkitt lymphoma or acute lymphoblastic leukemia. Cancer. 2006;106:1568–1580.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Duarte, USA

    Auayporn Nademanee

Authors
  1. Auayporn Nademanee
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. City of Hope Hospital, Duarte, California, USA

    Jasmine Zain

  2. Toni Stephenson Lymphoma Center, City of Hope Hospital, Duarte, California, USA

    Larry W. Kwak

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Cite this chapter

Nademanee, A. (2017). Burkitt lymphoma. In: Zain, J., Kwak, L. (eds) Management of Lymphomas: A Case-Based Approach. Adis, Cham. https://doi.org/10.1007/978-3-319-26827-9_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-26827-9_8

  • Published:

  • Publisher Name: Adis, Cham

  • Print ISBN: 978-3-319-26825-5

  • Online ISBN: 978-3-319-26827-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation